It inhibits tumor cell proliferation by blocking Raf-1, B-Raf, and kinase activities in the Ras/Raf/MEK/ERK signaling pathways while also reducing tumor angiogenesis by targeting vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and hepatocyte factor receptor (c-KIT) (83, 84). The gene discussed is BRAF; the disease is neoplasm.